Related Experiment Video

Updated: Jun 5, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials]

L Lorgis1, C Richard, M Zeller

  • 1Service de cardiologie, CHU Bocage, Boulevard du Maréchal-de-Lattre-de-Tassigny, 21034 Dijon, France.

Annales De Cardiologie Et D'Angeiologie
|January 18, 2011
PubMed

Insights

New anti-platelet agents like prasugrel and ticagrelor offer alternatives to clopidogrel for managing cardiovascular disease. Cardiologists must balance bleeding risk against ischemic benefits for optimal patient treatment.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease is a leading cause of mortality globally.
  • Anti-coagulants are crucial in acute cardiovascular event management.
  • Clopidogrel and aspirin combination is a standard treatment.

Purpose of the Study:

  • To review the role of newer P2Y12 receptor antagonists in cardiovascular disease management.
  • To compare the efficacy and safety of prasugrel and ticagrelor against clopidogrel.

Main Methods:

  • Review of major randomized trials comparing anti-platelet agents.
  • Analysis of clinical data on prasugrel and ticagrelor efficacy and safety.
  • Evaluation of the risk-benefit profile of different anti-platelet therapies.

Main Results:

  • Prasugrel and ticagrelor have demonstrated significant clinical benefits compared to clopidogrel.
  • These newer agents represent effective options within the P2Y12 receptor antagonist class.
  • Optimal drug selection requires careful consideration of individual patient risk factors.

Conclusions:

  • The availability of multiple effective P2Y12 receptor antagonists expands therapeutic options.
  • Cardiologists must individualize treatment by balancing ischemic protection and hemorrhage risk.
  • Tailoring anti-platelet therapy is key to optimizing outcomes in cardiovascular disease management.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...